Comparing Heska (HSKA) & Its Peers

Heska (NASDAQ: HSKA) is one of 89 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Heska to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

86.3% of Heska shares are held by institutional investors. Comparatively, 49.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.9% of Heska shares are held by company insiders. Comparatively, 16.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Heska and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Heska 7.53% 16.23% 11.93%
Heska Competitors -5,580.66% -62.18% -25.06%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Heska and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heska 0 1 5 0 2.83
Heska Competitors 452 1674 4484 148 2.64

Heska presently has a consensus price target of $103.10, suggesting a potential upside of 26.44%. As a group, “Biological products, except diagnostic” companies have a potential upside of 21.41%. Given Heska’s stronger consensus rating and higher possible upside, equities analysts plainly believe Heska is more favorable than its competitors.

Risk & Volatility

Heska has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Heska’s competitors have a beta of 1.59, indicating that their average stock price is 59% more volatile than the S&P 500.

Earnings and Valuation

This table compares Heska and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Heska $129.34 million $9.95 million 39.39
Heska Competitors $1.05 billion $96.04 million 1.50

Heska’s competitors have higher revenue and earnings than Heska. Heska is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Heska beats its competitors on 8 of the 13 factors compared.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply